[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Bristol-Myers Squibb Company is placed third among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader in oncology, immunology, cardiovascular disease, and fibrosis, is undergoing major strategic changes as it adapts to shifting market conditions. […]",
    "url": "https://finnhub.io/api/news?id=cb31122ec31f572338d5728faec9b4502de7a60da3953ba76066f1328e074a31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758668538,
      "headline": "Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment",
      "id": 136858213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Bristol-Myers Squibb Company is placed third among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader in oncology, immunology, cardiovascular disease, and fibrosis, is undergoing major strategic changes as it adapts to shifting market conditions. […]",
      "url": "https://finnhub.io/api/news?id=cb31122ec31f572338d5728faec9b4502de7a60da3953ba76066f1328e074a31"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM...",
    "url": "https://finnhub.io/api/news?id=740b1b758240942f4c0c974bdf743e2d766636d1cdbbd6b4d8174c5aa92145e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758633229,
      "headline": "Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript",
      "id": 136850780,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM...",
      "url": "https://finnhub.io/api/news?id=740b1b758240942f4c0c974bdf743e2d766636d1cdbbd6b4d8174c5aa92145e9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers says next-gen blood cancer drug hits goal in key study",
    "summary": "The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.",
    "url": "https://finnhub.io/api/news?id=d3d8db08205f67ecdb0a71fb2626ab34cf4aeca5801dd8842d7d14daef39aaff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758627660,
      "headline": "Bristol Myers says next-gen blood cancer drug hits goal in key study",
      "id": 136851174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.",
      "url": "https://finnhub.io/api/news?id=d3d8db08205f67ecdb0a71fb2626ab34cf4aeca5801dd8842d7d14daef39aaff"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma",
    "summary": "PRINCETON, N.J., September 23, 2025--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies",
    "url": "https://finnhub.io/api/news?id=d2279c21d0f601d38c7d39d1956008e58e88dffcfd1539d7ff6f761b75794ccd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758625140,
      "headline": "Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma",
      "id": 136851175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., September 23, 2025--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies",
      "url": "https://finnhub.io/api/news?id=d2279c21d0f601d38c7d39d1956008e58e88dffcfd1539d7ff6f761b75794ccd"
    }
  },
  {
    "ts": null,
    "headline": "Bull of the Day: Halozyme Therapeutics (HALO)",
    "summary": "The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth",
    "url": "https://finnhub.io/api/news?id=8b88e125a86554a6cf26e5a26ac76eeb8d32d9148bdc38602944c9b529868d26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758619200,
      "headline": "Bull of the Day: Halozyme Therapeutics (HALO)",
      "id": 136851176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth",
      "url": "https://finnhub.io/api/news?id=8b88e125a86554a6cf26e5a26ac76eeb8d32d9148bdc38602944c9b529868d26"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers advances research into multiple myeloma",
    "summary": "Bristol Myers announces that a Phase III study evaluating iberdomide in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma has met its interim...",
    "url": "https://finnhub.io/api/news?id=60e1bd3d3d19aa8920ee187046a327ec1ac6edf037b012985c181a983d9f4344",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758612810,
      "headline": "Bristol Myers advances research into multiple myeloma",
      "id": 136848946,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers announces that a Phase III study evaluating iberdomide in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma has met its interim...",
      "url": "https://finnhub.io/api/news?id=60e1bd3d3d19aa8920ee187046a327ec1ac6edf037b012985c181a983d9f4344"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason to Buy Bristol Myers Squibb Stock",
    "summary": "Find out why investors seeking passive income want shares of this dividend payer in their portfolio.",
    "url": "https://finnhub.io/api/news?id=fc07dc623bf09662b2914b28c86137f50d4a6ba65a650b1494463c8eb66ff754",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758612360,
      "headline": "1 Reason to Buy Bristol Myers Squibb Stock",
      "id": 136851177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Find out why investors seeking passive income want shares of this dividend payer in their portfolio.",
      "url": "https://finnhub.io/api/news?id=fc07dc623bf09662b2914b28c86137f50d4a6ba65a650b1494463c8eb66ff754"
    }
  }
]